SLC5A2 and type 2 diabetes mellitus: While combination therapy with SGLT-2 inhibitors and GLP-1 receptor agonists holds promise for addressing residual cardiovascular risk in type 2 diabetes, its optimal use requires nuanced consideration of patient subpopulations, safety, and cost-effectiveness.